Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced…

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune…

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the

Power Integrations Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SAN JOSÉ, Calif.--(BUSINESS WIRE)--Power Integrations (Nasdaq: POWI) today announced that on September 15, 2026 (the September Grant Date), it granted a total of 43,396 RSUs and 2,048 PSUs at target to fifteen employees who began their employment with Power Integrations in August 2026, and that on August 15, 2026 (the August Grant Date), it granted a total of 18,283 RSUs and 1,099 PSUs at target to nine employees who began their employment with …

New hires won’t vest BridgeBio stock until 2027

One-fourth of each award vests Nov. 16, 2027, with the balance vesting quarterly afterward if recipients remain employed; Nasdaq rules govern the grants.